157 related articles for article (PubMed ID: 38617527)
1. Comprehensive analysis of disulfidptosis-related lncRNAs for predicting prognosis and response of immunotherapy in pancreatic adenocarcinoma.
Guo J; Wang Y; Hou J; Zhao T; Wei Z
Transl Cancer Res; 2024 Mar; 13(3):1336-1350. PubMed ID: 38617527
[TBL] [Abstract][Full Text] [Related]
2. A disulfidptosis-related lncRNA signature for predicting prognosis and evaluating the tumor immune microenvironment of lung adenocarcinoma.
Song Z; Cao X; Wang X; Li Y; Zhang W; Wang Y; Chen L
Sci Rep; 2024 Feb; 14(1):4621. PubMed ID: 38409243
[TBL] [Abstract][Full Text] [Related]
3. Cuproptosis-related lncRNA scoring system to predict the clinical outcome and immune landscape in pancreatic adenocarcinoma.
Huang Y; Gong P; Su L; Zhang M
Sci Rep; 2023 Nov; 13(1):20870. PubMed ID: 38012210
[TBL] [Abstract][Full Text] [Related]
4. System analysis based on the pyroptosis-related genes identifies GSDMC as a novel therapy target for pancreatic adenocarcinoma.
Yan C; Niu Y; Li F; Zhao W; Ma L
J Transl Med; 2022 Oct; 20(1):455. PubMed ID: 36199146
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of a novel N6-methyladenosine (m6A)-related multi- long non-coding RNA (lncRNA) prognostic signature in pancreatic adenocarcinoma.
Yuan Q; Ren J; Li L; Li S; Xiang K; Shang D
Bioengineered; 2021 Dec; 12(1):2432-2448. PubMed ID: 34233576
[TBL] [Abstract][Full Text] [Related]
6. Disulfidptosis characterizes the tumor microenvironment and predicts immunotherapy sensitivity and prognosis in bladder cancer.
Pan G; Xie H; Xia Y
Heliyon; 2024 Feb; 10(3):e25573. PubMed ID: 38356551
[TBL] [Abstract][Full Text] [Related]
7. PANoptosis-related long non-coding RNA signature to predict the prognosis and immune landscapes of pancreatic adenocarcinoma.
Zhao Q; Ye Y; Zhang Q; Wu Y; Wang G; Gui Z; Zhang M
Biochem Biophys Rep; 2024 Mar; 37():101600. PubMed ID: 38371527
[TBL] [Abstract][Full Text] [Related]
8. Development and Validation of an Inflammatory Response-Related Gene Signature for Predicting the Prognosis of Pancreatic Adenocarcinoma.
Deng ZL; Zhou DZ; Cao SJ; Li Q; Zhang JF; Xie H
Inflammation; 2022 Aug; 45(4):1732-1751. PubMed ID: 35322324
[TBL] [Abstract][Full Text] [Related]
9. Identification of a disulfidptosis-related lncRNA signature for the prognostic and immune landscape prediction in head and neck squamous cell carcinoma.
Wei Z; Zhou C; Fang Y; Deng H; Shen Z
Discov Oncol; 2024 Mar; 15(1):75. PubMed ID: 38483698
[TBL] [Abstract][Full Text] [Related]
10. Development of a novel disulfidptosis-related lncRNA signature for prognostic and immune response prediction in clear cell renal cell carcinoma.
Wang N; Hu Y; Wang S; Xu Q; Jiao X; Wang Y; Yan L; Cao H; Shao F
Sci Rep; 2024 Jan; 14(1):624. PubMed ID: 38182642
[TBL] [Abstract][Full Text] [Related]
11. Construction of an efferocytosis-related long non-coding ribonucleic acid scoring system to predict clinical outcome and immunotherapy response in pancreatic adenocarcinoma.
Zhou C; Gan X; Sun S; Wang L; Zhang Y; Zhang J
Biochem Biophys Rep; 2023 Sep; 35():101540. PubMed ID: 37692763
[TBL] [Abstract][Full Text] [Related]
12. Tumor mutation burden-related long non-coding RNAs is predictor for prognosis and immune response in pancreatic cancer.
Wang C; Wang Z; Zhao Y; Jia R
BMC Gastroenterol; 2022 Nov; 22(1):495. PubMed ID: 36451085
[TBL] [Abstract][Full Text] [Related]
13. Construction of a cancer-associated fibroblasts-related long non-coding RNA signature to predict prognosis and immune landscape in pancreatic adenocarcinoma.
Ye Y; Zhao Q; Wu Y; Wang G; Huang Y; Sun W; Zhang M
Front Genet; 2022; 13():989719. PubMed ID: 36212154
[No Abstract] [Full Text] [Related]
14. Preliminary findings on the development of a predictive model for BLCA based on disulfidptosis-associated IncRNAs signature.
Tang C; Fan Y; Zhu S
BMC Urol; 2024 Mar; 24(1):69. PubMed ID: 38532369
[TBL] [Abstract][Full Text] [Related]
15. Construction of a novel disulfidptosis-related lncRNAs signature for prognosis prediction and anti-tumor immunity in laryngeal squamous cell carcinoma.
Zhang M; Sun Q; Han Z; Qin X; Gao T; Xu Y; Han S; Zhang Y; Liang Q; Guo Z; Liu J
Heliyon; 2024 May; 10(10):e30877. PubMed ID: 38774325
[TBL] [Abstract][Full Text] [Related]
16. Construction of a Novel Disulfidptosis-Related lncRNA Prognostic Signature in Pancreatic Cancer.
Xing F; Qin Y; Xu J; Wang W; Zhang B
Mol Biotechnol; 2023 Sep; ():. PubMed ID: 37733182
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of a novel ferroptosis‑related lncRNA prognostic signature for pancreatic adenocarcinoma.
Li J; Li W; Wang H; Ni B; Liu Y
Mol Med Rep; 2023 Feb; 27(2):. PubMed ID: 36660936
[TBL] [Abstract][Full Text] [Related]
18. A novel sphingolipid metabolism-related long noncoding RNA signature predicts the prognosis, immune landscape and therapeutic response in pancreatic adenocarcinoma.
He X; Xu Z; Ren R; Wan P; Zhang Y; Wang L; Han Y
Heliyon; 2024 Jan; 10(1):e23659. PubMed ID: 38173505
[TBL] [Abstract][Full Text] [Related]
19. Unraveling the role of disulfidptosis-related LncRNAs in colon cancer: a prognostic indicator for immunotherapy response, chemotherapy sensitivity, and insights into cell death mechanisms.
Chi H; Huang J; Yan Y; Jiang C; Zhang S; Chen H; Jiang L; Zhang J; Zhang Q; Yang G; Tian G
Front Mol Biosci; 2023; 10():1254232. PubMed ID: 37916187
[No Abstract] [Full Text] [Related]
20. Construction of a pancreatic cancer prediction model for oxidative stress-related lncRNA.
Huang H; Wei Y; Yao H; Chen M; Sun J
Funct Integr Genomics; 2023 Apr; 23(2):118. PubMed ID: 37020128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
